Emavusertib, alone or with ibrutinib, for lymphoma in the brain and spinal cord
Original title: CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to check safety and dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a pill called emavusertib in people whose lymphoma came back or stopped responding.
Who this trial is for. This trial is for adults whose blood cancer came back or did not respond to treatment. Later parts focus on lymphoma that started in the brain or spinal cord, testing emavusertib by itself and with a pill called ibrutinib.
Where it stands. The trial is checking how safe the drug is and how the body handles it. It is also checking how well the drug works against the cancer. The source reports no results, so the answers are not in yet.
What this means, and what it doesn't
What it could mean: This is one more idea being tested for lymphoma in the brain and spinal cord. Someone who thinks they might fit could ask their care team about it.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Joining one is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.